AzurRx BioPharma Increases Previously Announced Bought Deal to $5 0 Million forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Home / Top News / FMW Media, Inc.’s “New to The Street” TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ET
FMW Media, Inc.’s “New to The Street” TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ET
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) FMW Media’s “New to The Street” TV broadcasting its national syndicated 1- hour show, Sunday, May 16, 2021 on
NEWSMAX TV from 10-11AM ET.
“New To The Street’s” TV Sunday line-up features 6 interviews of the following Companies and their businesses representatives:
1).
subsidiary Black Bird Potentials’ interview with Mr. Eric Newlan, Vice-president and General Counsel,
The Investor Summit: AzurRx BioPharma Announces Participation in the Q2 Virtual Investor Summit
Delray Beach, Florida (Newsfile Corp. - May 11, 2021) -
AzurRx BioPharma (NASDAQ: AZRX) today announced that James Sapirstein, Chairman, President, and CEO will be attending the Q2 Virtual Investor Summit. Event Location
About AzurRx BioPharma
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis. AzurRx is also advancing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor; FW-1022, for COVID-19 GI infections and FW-420, for Grade 1 Immune Checkpoint Inhibi
Published: Jan 26, 2021
DELRAY BEACH, Fla., Jan. 26, 2021 (GLOBE NEWSWIRE) AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announced the activation of two additional clinical trial sites in Poland for the extension arm of the Phase 2b OPTION 2 study investigating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).
Additional sites were added in Europe to minimize any potential patient enrollment delays during the ongoing COVID-19 pandemic. The two sites in Poland, as well as the active clinical trial sites in the U.S., are actively enrolling patients, and the Company anticipates reporting topline data during the first quarter 2021.